Metoprolol-induced bradycardia
Pro Research Analysisby 
Searched over 200M research papers for "metoprolol-induced bradycardia"
Metoprolol-Induced Bradycardia: Prevalence and Risk Factors
Metoprolol, a commonly used beta-blocker, is well known to cause bradycardia, especially in certain patient populations. In heart failure patients with atrial fibrillation, metoprolol is associated with a higher prevalence of bradycardia compared to other beta-blockers like bucindolol. Patients on metoprolol experienced more frequent and severe bradycardia episodes, which often led to dose reductions and failure to reach target doses, potentially limiting the drug’s effectiveness in these patients .
Drug Interactions and Metoprolol Accumulation
Drug interactions can significantly increase the risk of metoprolol-induced bradycardia. For example, terbinafine, an antifungal agent, inhibits the CYP2D6 enzyme responsible for metoprolol metabolism. This inhibition leads to metoprolol accumulation and clinically significant bradycardia, as seen in a case where a patient developed severe bradycardia after starting terbinafine while on metoprolol . Similarly, propoxyphene, a pain medication, can also inhibit CYP2D6, resulting in life-threatening bradycardia when combined with metoprolol . However, not all CYP2D6-inhibiting antidepressants (like fluoxetine and paroxetine) have shown a significant increase in bradycardia risk when used with metoprolol in large population studies .
Genetic Factors: CYP2D6 Polymorphism and Bradycardia Risk
Genetic differences in CYP2D6 enzyme activity play a crucial role in metoprolol metabolism. Individuals who are poor metabolizers due to CYP2D6 polymorphisms have higher metoprolol plasma concentrations, leading to a greater reduction in heart rate and a higher risk of bradycardia. Meta-analyses and cohort studies confirm that poor metabolizers experience more bradycardia and lower heart rates compared to normal metabolizers, supporting the value of genetic testing for personalized dosing Meloche2020Collett2023.
Sex Differences in Metoprolol-Induced Bradycardia
Women are at a higher risk of metoprolol-induced bradycardia than men. Studies show that women have higher plasma concentrations of metoprolol at the same dose, resulting in a significantly greater reduction in heart rate and a much higher risk of bradycardia, even after adjusting for other risk factors .
Polypharmacy and Cumulative AV Block
The risk of bradycardia increases when metoprolol is combined with other drugs that slow atrioventricular (AV) nodal conduction, such as digoxin and diltiazem. In elderly patients, polypharmacy can lead to cumulative AV block and symptomatic bradycardia, especially when steady-state drug levels have not been reached or when drug interactions increase the levels of one or more agents .
Overdose and Acute Management
Metoprolol overdose can cause profound bradycardia, hypotension, and even cardiovascular collapse. Management typically involves gastric lavage and administration of glucagon as an antidote, with close cardiac monitoring .
Comparison with Other Rate-Control Agents
When compared to diltiazem for acute atrial fibrillation with rapid ventricular rate, metoprolol has a lower incidence of bradycardia as an adverse event. However, both drugs can cause bradycardia, and the overall risk of adverse events is similar between the two agents .
Conclusion
Metoprolol-induced bradycardia is a clinically significant concern, especially in patients with genetic predispositions, drug interactions, polypharmacy, and in women. Careful dose adjustment, consideration of drug–drug interactions, and genetic testing can help minimize the risk. Monitoring is essential, particularly in high-risk populations and when combining metoprolol with other AV nodal blocking agents.
Sources and full results
Most relevant research papers on this topic